Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone

Sandra Sotomayor, María J. Carmena, Andrew V Schally, Jozsef L. Varga, Manuel Sánchez-Chapado, Juan C. Prieto, Ana M. Bajo

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Receptors for vasoactive intestinal peptide (VIP) and the human epidermal growth factor family of tyrosine kinase receptors (HER) are potent promoters of cell proliferation, survival, migration, adhesion and differentiation in prostate cancer cell lines. In this study, we analyzed the cross-talk between both classes of receptors through the regulation of HER2 transactivation and expression by VIP. Three growth-hormone-releasing hormone analogs endowed with antagonistic activity for VIP receptors (JV-1-51, -52, and -53) abrogated the autocrine/paracrine stimuli of VIP on androgen-independent PC3 cells in the absence or the presence of 10% fetal bovine serum. Semiquantitative and real-time quantitative RT-PCR together with Western blotting showed increased expression levels of both mRNA and proteins for HER2 and HER3 in PC3 and androgen-dependent LNCaP prostate cancer cells as compared to non-neoplastic RWPE-1 cells. VIP (100 nM) stimulated the expression levels of both HER2 and HER3 in PC3 cells in a time-dependent manner. Whereas these effects were relatively slow, VIP rapidly (0.5 min) increased HER2 tyrosine phosphorylation. This pattern of HER transactivation was blocked by H89, a protein kinase A (PKA) inhibitor, as well as by the specific VIP antagonist JV-1-53, indicating the involvement of VIP receptors and PKA activity in phosphorylated HER2 formation. These findings support the merit of further studies on the potential usefulness of VIP receptor antagonists and both HER2 antibodies and tyrosine kinase inhibitors for prostate cancer therapy.

Original languageEnglish
Pages (from-to)1223-1230
Number of pages8
JournalInternational Journal of Oncology
Volume31
Issue number5
StatePublished - Nov 1 2007

Fingerprint

Growth Hormone-Releasing Hormone
Vasoactive Intestinal Peptide
Transcriptional Activation
Vasoactive Intestinal Peptide Receptors
Prostatic Neoplasms
Cyclic AMP-Dependent Protein Kinases
Androgens
Receptors, Vasoactive Intestinal Polypeptide, Type I
Receptor Protein-Tyrosine Kinases
Protein Kinase Inhibitors
Epidermal Growth Factor
Protein-Tyrosine Kinases
Tyrosine
Real-Time Polymerase Chain Reaction
Cell Survival
Western Blotting
Phosphorylation
Cell Proliferation
Cell Line
Messenger RNA

Keywords

  • Growth-hormone-releasing hormone analogs
  • HER2
  • HER3
  • Prostate cancer
  • Vasoactive intestinal peptide receptors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer : Antagonistic action of an analog of growth-hormone-releasing hormone. / Sotomayor, Sandra; Carmena, María J.; Schally, Andrew V; Varga, Jozsef L.; Sánchez-Chapado, Manuel; Prieto, Juan C.; Bajo, Ana M.

In: International Journal of Oncology, Vol. 31, No. 5, 01.11.2007, p. 1223-1230.

Research output: Contribution to journalArticle

Sotomayor, Sandra ; Carmena, María J. ; Schally, Andrew V ; Varga, Jozsef L. ; Sánchez-Chapado, Manuel ; Prieto, Juan C. ; Bajo, Ana M. / Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer : Antagonistic action of an analog of growth-hormone-releasing hormone. In: International Journal of Oncology. 2007 ; Vol. 31, No. 5. pp. 1223-1230.
@article{b30c74ccff2647be9ced14106b3ead61,
title = "Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone",
abstract = "Receptors for vasoactive intestinal peptide (VIP) and the human epidermal growth factor family of tyrosine kinase receptors (HER) are potent promoters of cell proliferation, survival, migration, adhesion and differentiation in prostate cancer cell lines. In this study, we analyzed the cross-talk between both classes of receptors through the regulation of HER2 transactivation and expression by VIP. Three growth-hormone-releasing hormone analogs endowed with antagonistic activity for VIP receptors (JV-1-51, -52, and -53) abrogated the autocrine/paracrine stimuli of VIP on androgen-independent PC3 cells in the absence or the presence of 10{\%} fetal bovine serum. Semiquantitative and real-time quantitative RT-PCR together with Western blotting showed increased expression levels of both mRNA and proteins for HER2 and HER3 in PC3 and androgen-dependent LNCaP prostate cancer cells as compared to non-neoplastic RWPE-1 cells. VIP (100 nM) stimulated the expression levels of both HER2 and HER3 in PC3 cells in a time-dependent manner. Whereas these effects were relatively slow, VIP rapidly (0.5 min) increased HER2 tyrosine phosphorylation. This pattern of HER transactivation was blocked by H89, a protein kinase A (PKA) inhibitor, as well as by the specific VIP antagonist JV-1-53, indicating the involvement of VIP receptors and PKA activity in phosphorylated HER2 formation. These findings support the merit of further studies on the potential usefulness of VIP receptor antagonists and both HER2 antibodies and tyrosine kinase inhibitors for prostate cancer therapy.",
keywords = "Growth-hormone-releasing hormone analogs, HER2, HER3, Prostate cancer, Vasoactive intestinal peptide receptors",
author = "Sandra Sotomayor and Carmena, {Mar{\'i}a J.} and Schally, {Andrew V} and Varga, {Jozsef L.} and Manuel S{\'a}nchez-Chapado and Prieto, {Juan C.} and Bajo, {Ana M.}",
year = "2007",
month = "11",
day = "1",
language = "English",
volume = "31",
pages = "1223--1230",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer

T2 - Antagonistic action of an analog of growth-hormone-releasing hormone

AU - Sotomayor, Sandra

AU - Carmena, María J.

AU - Schally, Andrew V

AU - Varga, Jozsef L.

AU - Sánchez-Chapado, Manuel

AU - Prieto, Juan C.

AU - Bajo, Ana M.

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Receptors for vasoactive intestinal peptide (VIP) and the human epidermal growth factor family of tyrosine kinase receptors (HER) are potent promoters of cell proliferation, survival, migration, adhesion and differentiation in prostate cancer cell lines. In this study, we analyzed the cross-talk between both classes of receptors through the regulation of HER2 transactivation and expression by VIP. Three growth-hormone-releasing hormone analogs endowed with antagonistic activity for VIP receptors (JV-1-51, -52, and -53) abrogated the autocrine/paracrine stimuli of VIP on androgen-independent PC3 cells in the absence or the presence of 10% fetal bovine serum. Semiquantitative and real-time quantitative RT-PCR together with Western blotting showed increased expression levels of both mRNA and proteins for HER2 and HER3 in PC3 and androgen-dependent LNCaP prostate cancer cells as compared to non-neoplastic RWPE-1 cells. VIP (100 nM) stimulated the expression levels of both HER2 and HER3 in PC3 cells in a time-dependent manner. Whereas these effects were relatively slow, VIP rapidly (0.5 min) increased HER2 tyrosine phosphorylation. This pattern of HER transactivation was blocked by H89, a protein kinase A (PKA) inhibitor, as well as by the specific VIP antagonist JV-1-53, indicating the involvement of VIP receptors and PKA activity in phosphorylated HER2 formation. These findings support the merit of further studies on the potential usefulness of VIP receptor antagonists and both HER2 antibodies and tyrosine kinase inhibitors for prostate cancer therapy.

AB - Receptors for vasoactive intestinal peptide (VIP) and the human epidermal growth factor family of tyrosine kinase receptors (HER) are potent promoters of cell proliferation, survival, migration, adhesion and differentiation in prostate cancer cell lines. In this study, we analyzed the cross-talk between both classes of receptors through the regulation of HER2 transactivation and expression by VIP. Three growth-hormone-releasing hormone analogs endowed with antagonistic activity for VIP receptors (JV-1-51, -52, and -53) abrogated the autocrine/paracrine stimuli of VIP on androgen-independent PC3 cells in the absence or the presence of 10% fetal bovine serum. Semiquantitative and real-time quantitative RT-PCR together with Western blotting showed increased expression levels of both mRNA and proteins for HER2 and HER3 in PC3 and androgen-dependent LNCaP prostate cancer cells as compared to non-neoplastic RWPE-1 cells. VIP (100 nM) stimulated the expression levels of both HER2 and HER3 in PC3 cells in a time-dependent manner. Whereas these effects were relatively slow, VIP rapidly (0.5 min) increased HER2 tyrosine phosphorylation. This pattern of HER transactivation was blocked by H89, a protein kinase A (PKA) inhibitor, as well as by the specific VIP antagonist JV-1-53, indicating the involvement of VIP receptors and PKA activity in phosphorylated HER2 formation. These findings support the merit of further studies on the potential usefulness of VIP receptor antagonists and both HER2 antibodies and tyrosine kinase inhibitors for prostate cancer therapy.

KW - Growth-hormone-releasing hormone analogs

KW - HER2

KW - HER3

KW - Prostate cancer

KW - Vasoactive intestinal peptide receptors

UR - http://www.scopus.com/inward/record.url?scp=38449095743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449095743&partnerID=8YFLogxK

M3 - Article

C2 - 17912451

AN - SCOPUS:38449095743

VL - 31

SP - 1223

EP - 1230

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 5

ER -